-
1
-
-
78751621217
-
Evolving epidemiology of hepatitis C virus
-
D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
-
(2011)
Clin Microbiol Infect
, vol.17
, pp. 107-115
-
-
Lavanchy, D.1
-
2
-
-
23944506014
-
Global epidemiology of hepatitis C virus infection
-
DOI 10.1016/S1473-3099(05)70216-4, PII S1473309905702164
-
C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567 (Pubitemid 41196755)
-
(2005)
Lancet Infectious Diseases
, vol.5
, Issue.9
, pp. 558-567
-
-
Shepard, C.W.1
Finelli, L.2
Alter, M.J.3
-
3
-
-
33646250428
-
The natural history of hepatitis C virus (HCV) infection
-
S.L. Chen, and T.R. Morgan The natural history of hepatitis C virus (HCV) infection Int J Med Sci 3 2006 47 52
-
(2006)
Int J Med Sci
, vol.3
, pp. 47-52
-
-
Chen, S.L.1
Morgan, T.R.2
-
4
-
-
77953607625
-
Pegylated-interferon plus ribavirin therapy in the treatment of CHC: Individualization of treatment duration according to on-treatment virologic response
-
S. Zeuzem, and F. Poordad Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response Curr Med Res Opin 26 2010 1733 1743
-
(2010)
Curr Med Res Opin
, vol.26
, pp. 1733-1743
-
-
Zeuzem, S.1
Poordad, F.2
-
5
-
-
84898990930
-
New hepatitis C therapies: The toolbox, strategies, and challenges
-
J. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176 1192
-
(2014)
Gastroenterology
, vol.146
, pp. 1176-1192
-
-
Pawlotsky, J.1
-
6
-
-
84901586232
-
Hepatitis C treatment: An incipient therapeutic revolution
-
10.1016/j.molmed.2014.02. 002
-
A.S. deLemos, and R.T. Chung Hepatitis C treatment: an incipient therapeutic revolution Trends Mol Med 2014 10.1016/j.molmed.2014.02. 002
-
(2014)
Trends Mol Med
-
-
Delemos, A.S.1
Chung, R.T.2
-
8
-
-
84872044131
-
New therapeutic strategies in HCV: Second-generation protease inhibitors
-
V.C. Clark, J.A. Peter, and D.R. Nelson New therapeutic strategies in HCV: second-generation protease inhibitors Liver Int 33 Suppl. 1 2013 80 84
-
(2013)
Liver Int
, vol.33
, Issue.SUPPL. 1
, pp. 80-84
-
-
Clark, V.C.1
Peter, J.A.2
Nelson, D.R.3
-
9
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, and N. Boparai et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
Jacobson, I.M.7
Reddy, K.R.8
Goodman, Z.D.9
Boparai, N.10
-
10
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, and R. Flisiak et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
Marcellin, P.7
Muir, A.J.8
Ferenci, P.9
Flisiak, R.10
-
11
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G.R. Foster, and A. Horban et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.4
Diago, M.5
Roberts, S.6
Focaccia, R.7
Younossi, Z.8
Foster, G.R.9
Horban, A.10
-
12
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, Z.D. Goodman, H.L. Sings, and N. Boparai et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
Poordad, F.7
Goodman, Z.D.8
Sings, H.L.9
Boparai, N.10
-
13
-
-
84874117254
-
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis
-
S. Bruno, J.M. Vierling, R. Esteban, L.M. Nyberg, H. Tanno, Z. Goodman, F. Poordad, B. Bacon, K. Gottesdiener, and L.D. Pedicone et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis J Hepatol 58 2013 479 487
-
(2013)
J Hepatol
, vol.58
, pp. 479-487
-
-
Bruno, S.1
Vierling, J.M.2
Esteban, R.3
Nyberg, L.M.4
Tanno, H.5
Goodman, Z.6
Poordad, F.7
Bacon, B.8
Gottesdiener, K.9
Pedicone, L.D.10
-
14
-
-
84882908504
-
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
-
C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, V. Canva, V. de Ledinghen, T. Poynard, D. Samuel, and M. Bourlière et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
-
(2013)
J Hepatol
, vol.59
, pp. 434-441
-
-
Hézode, C.1
Fontaine, H.2
Dorival, C.3
Larrey, D.4
Zoulim, F.5
Canva, V.6
De Ledinghen, V.7
Poynard, T.8
Samuel, D.9
Bourlière, M.10
-
15
-
-
84879799809
-
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial
-
M.S. Sulkowski, K.E. Sherman, D.T. Dieterich, M. Bsharat, L. Mahnke, J.K. Rockstroh, S. Gharakhanian, S. McCallister, J. Henshaw, and P.-M. Girard et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial Ann Intern Med 159 2013 86 96
-
(2013)
Ann Intern Med
, vol.159
, pp. 86-96
-
-
Sulkowski, M.S.1
Sherman, K.E.2
Dieterich, D.T.3
Bsharat, M.4
Mahnke, L.5
Rockstroh, J.K.6
Gharakhanian, S.7
McCallister, S.8
Henshaw, J.9
Girard, P.-M.10
-
16
-
-
84879795434
-
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial
-
M. Sulkowski, S. Pol, J. Mallolas, H. Fainboim, C. Cooper, J. Slim, A. Rivero, C. Mak, S. Thompson, and A.Y.M. Howe et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial Lancet Infect Dis 13 2013 597 605
-
(2013)
Lancet Infect Dis
, vol.13
, pp. 597-605
-
-
Sulkowski, M.1
Pol, S.2
Mallolas, J.3
Fainboim, H.4
Cooper, C.5
Slim, J.6
Rivero, A.7
Mak, C.8
Thompson, S.9
Howe, A.Y.M.10
-
17
-
-
84891825080
-
Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection
-
D.E. Karageorgopoulos, O. El-Sherif, S. Bhagani, and S.H. Khoo Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection Curr Opin Infect Dis 27 2014 36 45
-
(2014)
Curr Opin Infect Dis
, vol.27
, pp. 36-45
-
-
Karageorgopoulos, D.E.1
El-Sherif, O.2
Bhagani, S.3
Khoo, S.H.4
-
18
-
-
84890973133
-
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C
-
J.-P. Bronowicki, S. Pol, P.J. Thuluvath, D. Larrey, C.T. Martorell, V.K. Rustgi, D.W. Morris, Z. Younes, M.W. Fried, and M. Bourlière et al. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C Antivir Ther 18 2013 885 893
-
(2013)
Antivir Ther
, vol.18
, pp. 885-893
-
-
Bronowicki, J.-P.1
Pol, S.2
Thuluvath, P.J.3
Larrey, D.4
Martorell, C.T.5
Rustgi, V.K.6
Morris, D.W.7
Younes, Z.8
Fried, M.W.9
Bourlière, M.10
-
19
-
-
84879693219
-
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
-
Y. Suzuki, K. Ikeda, F. Suzuki, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, H. Ishikawa, H. Watanabe, and W. Hu et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 58 2013 655 662
-
(2013)
J Hepatol
, vol.58
, pp. 655-662
-
-
Suzuki, Y.1
Ikeda, K.2
Suzuki, F.3
Toyota, J.4
Karino, Y.5
Chayama, K.6
Kawakami, Y.7
Ishikawa, H.8
Watanabe, H.9
Hu, W.10
-
20
-
-
84892761609
-
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection
-
G.T. Everson, K.D. Sims, M. Rodriguez-Torres, C. Hézode, E. Lawitz, M. Bourlière, V. Loustaud-Ratti, V. Rustgi, H. Schwartz, and H. Tatum et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection Gastroenterology 146 2014 420 429
-
(2014)
Gastroenterology
, vol.146
, pp. 420-429
-
-
Everson, G.T.1
Sims, K.D.2
Rodriguez-Torres, M.3
Hézode, C.4
Lawitz, E.5
Bourlière, M.6
Loustaud-Ratti, V.7
Rustgi, V.8
Schwartz, H.9
Tatum, H.10
-
21
-
-
84885308430
-
Drug-drug interactions during antiviral therapy for chronic hepatitis C
-
J. Kiser, J. Burton, and G. Everson Drug-drug interactions during antiviral therapy for chronic hepatitis C Nat Rev Gastroenterol Hepatol 10 2013 596 606
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, pp. 596-606
-
-
Kiser, J.1
Burton, J.2
Everson, G.3
-
22
-
-
84865563661
-
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study
-
M.P. Manns, E. Gane, M. Rodriguez-Torres, A. Stoehr, C.-T. Yeh, P. Marcellin, R.T. Wiedmann, P.M. Hwang, L. Caro, and R.J.O. Barnard et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study Hepatology 56 2012 884 893
-
(2012)
Hepatology
, vol.56
, pp. 884-893
-
-
Manns, M.P.1
Gane, E.2
Rodriguez-Torres, M.3
Stoehr, A.4
Yeh, C.-T.5
Marcellin, P.6
Wiedmann, R.T.7
Hwang, P.M.8
Caro, L.9
Barnard, R.J.O.10
-
23
-
-
84879189258
-
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment
-
E. Lawitz, M. Rodriguez-Torres, A. Stoehr, E.J. Gane, L. Serfaty, S. Bhanja, R.J. Barnard, D. An, J. Gress, and P. Hwang et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment J Hepatol 59 2013 11 17
-
(2013)
J Hepatol
, vol.59
, pp. 11-17
-
-
Lawitz, E.1
Rodriguez-Torres, M.2
Stoehr, A.3
Gane, E.J.4
Serfaty, L.5
Bhanja, S.6
Barnard, R.J.7
An, D.8
Gress, J.9
Hwang, P.10
-
24
-
-
84903126518
-
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis
-
M. Rodriguez-Torres, A. Stoehr, E.J. Gane, L. Serfaty, E. Lawitz, A. Zhou, M. Bourque, S. Bhanja, J. Strizki, and R.J.O. Barnard et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis Clin Gastroenterol Hepatol 3565 2013
-
(2013)
Clin Gastroenterol Hepatol
, vol.3565
-
-
Rodriguez-Torres, M.1
Stoehr, A.2
Gane, E.J.3
Serfaty, L.4
Lawitz, E.5
Zhou, A.6
Bourque, M.7
Bhanja, S.8
Strizki, J.9
Barnard, R.J.O.10
-
25
-
-
84884550531
-
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
-
E. Lawitz, M. Sulkowski, I. Jacobson, W.K. Kraft, B. Maliakkal, M. Al-Ibrahim, S.C. Gordon, P. Kwo, J.K. Rockstroh, and P. Panorchan et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics Antivir Res 99 2013 214 220
-
(2013)
Antivir Res
, vol.99
, pp. 214-220
-
-
Lawitz, E.1
Sulkowski, M.2
Jacobson, I.3
Kraft, W.K.4
Maliakkal, B.5
Al-Ibrahim, M.6
Gordon, S.C.7
Kwo, P.8
Rockstroh, J.K.9
Panorchan, P.10
-
26
-
-
84884411153
-
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with HCV genotype 1 infection
-
790.e3-800.e3
-
P. Marcellin, C. Cooper, L. Balart, D. Larrey, T. Box, E. Yoshida, E. Lawitz, P. Buggisch, P. Ferenci, and M. Weltman et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with HCV genotype 1 infection Gastroenterology 145 2013 790.e3-800.e3
-
(2013)
Gastroenterology
, vol.145
-
-
Marcellin, P.1
Cooper, C.2
Balart, L.3
Larrey, D.4
Box, T.5
Yoshida, E.6
Lawitz, E.7
Buggisch, P.8
Ferenci, P.9
Weltman, M.10
-
27
-
-
84921032324
-
DAUPHINE: A randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4
-
10.1111/liv.12471
-
G. Everson, C. Cooper, C. Hézode, M.L. Shiffman, E. Yoshida, T. Beltran-Jaramillo, P. Andreone, S. Bruno, P. Ferenci, and S. Zeuzem et al. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4 Liver Int 2014 10.1111/liv.12471
-
(2014)
Liver Int
-
-
Everson, G.1
Cooper, C.2
Hézode, C.3
Shiffman, M.L.4
Yoshida, E.5
Beltran-Jaramillo, T.6
Andreone, P.7
Bruno, S.8
Ferenci, P.9
Zeuzem, S.10
-
28
-
-
84893454551
-
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders
-
E.J. Gane, R. Rouzier, A. Wiercinska-Drapalo, D.G. Larrey, P.N. Morcos, B.J. Brennan, S. Le Pogam, I. Nájera, R. Petric, and J.Q. Tran et al. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders Antimicrob Agents Chemother 58 2014 1136 1145
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 1136-1145
-
-
Gane, E.J.1
Rouzier, R.2
Wiercinska-Drapalo, A.3
Larrey, D.G.4
Morcos, P.N.5
Brennan, B.J.6
Le Pogam, S.7
Nájera, I.8
Petric, R.9
Tran, J.Q.10
-
29
-
-
84921028832
-
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
-
10.1111/liv.12588
-
E.J. Gane, P.J. Pockros, S. Zeuzem, P. Marcellin, A. Shikhman, C. Bernaards, J. Zhou, E.S. Yetzer, R. Ballester, and C. Dwyer et al. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study Liver Int 2014 10.1111/liv.12588
-
(2014)
Liver Int
-
-
Gane, E.J.1
Pockros, P.J.2
Zeuzem, S.3
Marcellin, P.4
Shikhman, A.5
Bernaards, C.6
Zhou, J.7
Yetzer, E.S.8
Ballester, R.9
Dwyer, C.10
-
30
-
-
84899068302
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, D. Crawford, O. Weiland, H. Aguilar, J. Xiong, and T. Pilot-Matias et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
-
(2014)
N Engl J Med
, vol.370
, pp. 1594-1603
-
-
Feld, J.J.1
Kowdley, K.V.2
Coakley, E.3
Sigal, S.4
Nelson, D.R.5
Crawford, D.6
Weiland, O.7
Aguilar, H.8
Xiong, J.9
Pilot-Matias, T.10
-
31
-
-
84899106124
-
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
S. Zeuzem, I.M. Jacobson, T. Baykal, R.T. Marinho, F. Poordad, M. Bourlière, M.S. Sulkowski, H. Wedemeyer, E. Tam, and P. Desmond et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
-
(2014)
N Engl J Med
, vol.370
, pp. 1604-1614
-
-
Zeuzem, S.1
Jacobson, I.M.2
Baykal, T.3
Marinho, R.T.4
Poordad, F.5
Bourlière, M.6
Sulkowski, M.S.7
Wedemeyer, H.8
Tam, E.9
Desmond, P.10
-
32
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
10.1056/NEJMoa1402338
-
P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E. Tam, R.T. Marinho, N. Tsai, and A. Nyberg et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 2014 10.1056/NEJMoa1402338
-
(2014)
N Engl J Med
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
Cohen, D.4
Luo, Y.5
Cooper, C.6
Tam, E.7
Marinho, R.T.8
Tsai, N.9
Nyberg, A.10
-
33
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
10.1056/NEJMoa1402869
-
F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, K. Agarwal, M.L. Shiffman, H. Wedemeyer, T. Berg, and E.M. Yoshida et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 2014 10.1056/NEJMoa1402869
-
(2014)
N Engl J Med
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
Kowdley, K.V.4
Zeuzem, S.5
Agarwal, K.6
Shiffman, M.L.7
Wedemeyer, H.8
Berg, T.9
Yoshida, E.M.10
-
34
-
-
84903301263
-
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection
-
10.1002/hep.27053
-
D.L. Wyles, M. Rodriguez-Torres, E. Lawitz, M.L. Shiffman, S. Pol, R.W. Herring, B. Massetto, B. Kanwar, J.D. Trenkle, and P.S. Pang et al. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection Hepatology 2014 10.1002/hep.27053
-
(2014)
Hepatology
-
-
Wyles, D.L.1
Rodriguez-Torres, M.2
Lawitz, E.3
Shiffman, M.L.4
Pol, S.5
Herring, R.W.6
Massetto, B.7
Kanwar, B.8
Trenkle, J.D.9
Pang, P.S.10
-
35
-
-
84904708963
-
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis
-
10.1053/j.gastro.2014.04.006
-
M.P. Manns, J.M. Vierling, B.R. Bacon, S. Bruno, O. Shibolet, Y. Baruch, P. Marcellin, L. Caro, A.Y. Howe, and C. Fandozzi et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis Gastroenterology 2014 10.1053/j.gastro.2014.04.006
-
(2014)
Gastroenterology
-
-
Manns, M.P.1
Vierling, J.M.2
Bacon, B.R.3
Bruno, S.4
Shibolet, O.5
Baruch, Y.6
Marcellin, P.7
Caro, L.8
Howe, A.Y.9
Fandozzi, C.10
-
36
-
-
78049493632
-
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
-
J. De Bruijne, J.F. Bergmann, H.W. Reesink, C.J. Weegink, R. Molenkamp, J. Schinkel, X. Tong, J. Li, M.A. Treitel, and E.A. Hughes et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients Hepatology 52 2010 1590 1599
-
(2010)
Hepatology
, vol.52
, pp. 1590-1599
-
-
De Bruijne, J.1
Bergmann, J.F.2
Reesink, H.W.3
Weegink, C.J.4
Molenkamp, R.5
Schinkel, J.6
Tong, X.7
Li, J.8
Treitel, M.A.9
Hughes, E.A.10
-
37
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, G.T. Everson, M.W. Fried, M. Adler, H.W. Reesink, and M. Martin et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
-
(2011)
N Engl J Med
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
Nelson, D.R.4
Sulkowski, M.S.5
Everson, G.T.6
Fried, M.W.7
Adler, M.8
Reesink, H.W.9
Martin, M.10
-
38
-
-
84892806505
-
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
-
e6
-
S. Zeuzem, T. Berg, E. Gane, P. Ferenci, G.R. Foster, M.W. Fried, C. Hezode, G.M. Hirschfield, I. Jacobson, and I. Nikitin et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2014 430 441 e6
-
(2014)
Gastroenterology
, vol.146
, pp. 430-441
-
-
Zeuzem, S.1
Berg, T.2
Gane, E.3
Ferenci, P.4
Foster, G.R.5
Fried, M.W.6
Hezode, C.7
Hirschfield, G.M.8
Jacobson, I.9
Nikitin, I.10
-
39
-
-
78049316315
-
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease
-
P.W. White, M. Llinàs-Brunet, M. Amad, R.C. Bethell, G. Bolger, M.G. Cordingley, J. Duan, M. Garneau, L. Lagacé, and D. Thibeault et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease Antimicrob Agents Chemother 54 2010 4611 4618
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 4611-4618
-
-
White, P.W.1
Llinàs-Brunet, M.2
Amad, M.3
Bethell, R.C.4
Bolger, G.5
Cordingley, M.G.6
Duan, J.7
Garneau, M.8
Lagacé, L.9
Thibeault, D.10
-
40
-
-
84871765489
-
Exploratory study of oral combination antiviral therapy for hepatitis C
-
F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, S. Siggelkow, M. Heckaman, L. Larsen, R. Menon, and G. Koev et al. Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
-
(2013)
N Engl J Med
, vol.368
, pp. 45-53
-
-
Poordad, F.1
Lawitz, E.2
Kowdley, K.V.3
Cohen, D.E.4
Podsadecki, T.5
Siggelkow, S.6
Heckaman, M.7
Larsen, L.8
Menon, R.9
Koev, G.10
-
41
-
-
84894378216
-
Differential sensitivity of 5′UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors
-
812.e4-821.e4
-
Y.-P. Li, S. Ramirez, D. Humes, S.B. Jensen, J.M. Gottwein, and J. Bukh Differential sensitivity of 5′UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors Gastroenterology 146 2014 812.e4-821.e4
-
(2014)
Gastroenterology
, vol.146
-
-
Li, Y.-P.1
Ramirez, S.2
Humes, D.3
Jensen, S.B.4
Gottwein, J.M.5
Bukh, J.6
-
42
-
-
84896292745
-
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection
-
P.M. Scola, L.-Q. Sun, A.X. Wang, J. Chen, N. Sin, B.L. Venables, S.-Y. Sit, Y. Chen, A. Cocuzza, and D.M. Bilder et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection J Med Chem 57 2014 1730 1752
-
(2014)
J Med Chem
, vol.57
, pp. 1730-1752
-
-
Scola, P.M.1
Sun, L.-Q.2
Wang, A.X.3
Chen, J.4
Sin, N.5
Venables, B.L.6
Sit, S.-Y.7
Chen, Y.8
Cocuzza, A.9
Bilder, D.M.10
-
43
-
-
84874095900
-
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses
-
J.M. Gottwein, S.B. Jensen, Y.P. Li, L. Ghanem, T.K. Scheel, S.B. Serre, L. Mikkelsen, and J. Bukh Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses Antimicrob Agents Chemother 57 2013 1291 1303
-
(2013)
Antimicrob Agents Chemother
, vol.57
, pp. 1291-1303
-
-
Gottwein, J.M.1
Jensen, S.B.2
Li, Y.P.3
Ghanem, L.4
Scheel, T.K.5
Serre, S.B.6
Mikkelsen, L.7
Bukh, J.8
-
44
-
-
73849106636
-
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease
-
N.J. Liverton, S.S. Carroll, J. Dimuzio, C. Fandozzi, D.J. Graham, D. Hazuda, M.K. Holloway, S.W. Ludmerer, J.A. McCauley, and C.J. McIntyre et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob Agents Chemother 54 2010 305 311
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 305-311
-
-
Liverton, N.J.1
Carroll, S.S.2
Dimuzio, J.3
Fandozzi, C.4
Graham, D.J.5
Hazuda, D.6
Holloway, M.K.7
Ludmerer, S.W.8
McCauley, J.A.9
McIntyre, C.J.10
-
45
-
-
84896275496
-
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease
-
Y. Jiang, S.W. Andrews, K.R. Condroski, B. Buckman, V. Serebryany, S. Wenglowsky, A.L. Kennedy, M.R. Madduru, B. Wang, and M. Lyon et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease J Med Chem 57 2014 1753 1769
-
(2014)
J Med Chem
, vol.57
, pp. 1753-1769
-
-
Jiang, Y.1
Andrews, S.W.2
Condroski, K.R.3
Buckman, B.4
Serebryany, V.5
Wenglowsky, S.6
Kennedy, A.L.7
Madduru, M.R.8
Wang, B.9
Lyon, M.10
-
46
-
-
84893514771
-
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451
-
H. Yang, M. Robinson, A.C. Corsa, B. Peng, G. Cheng, Y. Tian, Y. Wang, R. Pakdaman, M. Shen, and X. Qi et al. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451 Antimicrob Agents Chemother 58 2014 647 653
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 647-653
-
-
Yang, H.1
Robinson, M.2
Corsa, A.C.3
Peng, B.4
Cheng, G.5
Tian, Y.6
Wang, Y.7
Pakdaman, R.8
Shen, M.9
Qi, X.10
-
47
-
-
84864387126
-
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants
-
V. Summa, S.W. Ludmerer, J.A. McCauley, C. Fandozzi, C. Burlein, G. Claudio, P.J. Coleman, J.M. DiMuzio, M. Ferrara, and M. Di Filippo et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 4161-4167
-
-
Summa, V.1
Ludmerer, S.W.2
McCauley, J.A.3
Fandozzi, C.4
Burlein, C.5
Claudio, G.6
Coleman, P.J.7
Dimuzio, J.M.8
Ferrara, M.9
Di Filippo, M.10
-
48
-
-
84862786885
-
Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity
-
X.C. Sheng, A. Casarez, R. Cai, M.O. Clarke, X. Chen, A. Cho, W.E. Delaney IV, E. Doerffler, M. Ji, and M. Mertzman et al. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity Bioorg Med Chem Lett 22 2012 1394 1396
-
(2012)
Bioorg Med Chem Lett
, vol.22
, pp. 1394-1396
-
-
Sheng, X.C.1
Casarez, A.2
Cai, R.3
Clarke, M.O.4
Chen, X.5
Cho, A.6
Delaney, I.V.W.E.7
Doerffler, E.8
Ji, M.9
Mertzman, M.10
-
49
-
-
77952602256
-
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease
-
X. Tong, A. Arasappan, F. Bennett, R. Chase, B. Feld, Z. Guo, A. Hart, V. Madison, B. Malcolm, and J. Pichardo et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease Antimicrob Agents Chemother 54 2010 2365 2370
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 2365-2370
-
-
Tong, X.1
Arasappan, A.2
Bennett, F.3
Chase, R.4
Feld, B.5
Guo, Z.6
Hart, A.7
Madison, V.8
Malcolm, B.9
Pichardo, J.10
-
50
-
-
84861679675
-
Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: A novel macrocyclic HCV protease inhibitor
-
J. De Bruijne, A. van Vliet, C.J. Weegink, W. Mazur, A. Wiercinska-Drapało, K. Simon, G. Cholewińska-Szymańska, J. Kapocsi, I. Várkonyi, and X.-J. Zhou et al. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor Antivir Ther 17 2012 633 642
-
(2012)
Antivir Ther
, vol.17
, pp. 633-642
-
-
De Bruijne, J.1
Van Vliet, A.2
Weegink, C.J.3
Mazur, W.4
Wiercinska- Drapało, A.5
Simon, K.6
Cholewińska-Szymańska, G.7
Kapocsi, J.8
Várkonyi, I.9
Zhou, X.-J.10
-
51
-
-
84895802673
-
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
-
D.L. Wyles, and J.A. Gutierrez Importance of HCV genotype 1 subtypes for drug resistance and response to therapy J Viral Hepat 21 2014 229 240
-
(2014)
J Viral Hepat
, vol.21
, pp. 229-240
-
-
Wyles, D.L.1
Gutierrez, J.A.2
-
52
-
-
84866323328
-
Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients
-
H. Dvory-Sobol, K.A. Wong, K.S. Ku, A. Bae, E.J. Lawitz, P.S. Pang, J. Harris, M.D. Miller, and H. Mo Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients Antimicrob Agents Chemother 56 2012 5289 5295
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 5289-5295
-
-
Dvory-Sobol, H.1
Wong, K.A.2
Ku, K.S.3
Bae, A.4
Lawitz, E.J.5
Pang, P.S.6
Harris, J.7
Miller, M.D.8
Mo, H.9
|